Related content

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

By Lynde Charles  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 1-3

Springer Publishing Company

Access to resources Recommend Favorite

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

By Revicki Dennis   Willian Mary Kaye   Menter Alan   Gordon Kenneth   Kimball Alexa   Leonardi Craig   Langley Richard   Kimel Miriam   Okun Martin  

Journal of Dermatological Treatment, Vol. 18, Iss. 6, 2007-01 ,pp. : 341-350

Informa Healthcare

Access to resources Recommend Favorite

Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite

Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data. Part II

By Papp Kim   Camisa Charles   Stone Stephen   Caro Ivor   Wang Xiaolin   Compton Peter   Walicke Patricia   Gottlieb Alice  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 313-323

Springer Publishing Company

Access to resources Recommend Favorite

Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: A comparative study

By Ranjan Nitin   Sharma Nand Lal   Shanker Vinay   Mahajan Vikram   Tegta Gita Ram  

Journal of Dermatological Treatment, Vol. 18, Iss. 5, 2007-01 ,pp. : 295-300

Informa Healthcare

Access to resources Recommend Favorite